Literature DB >> 19780195

Characterization of relapsing-remitting and chronic forms of experimental autoimmune encephalomyelitis in C57BL/6 mice.

Jennifer L Berard1, Kevin Wolak, Sylvie Fournier, Samuel David.   

Abstract

Multiple sclerosis (MS) is an autoimmune, demyelinating disease of the central nervous system (CNS). Like MS, the animal model experimental autoimmune encephalomyelitis (EAE) is characterized by CNS inflammation and demyelination and can follow a relapsing-remitting (RR) or chronic (CH) disease course. The molecular and pathological differences that underlie these different forms of EAE are not fully understood. We have compared the differences in RR- and CH-EAE generated in the same mouse strain (C57BL/6) using the same antigen. At the peak of disease when mice in both groups have similar clinical scores, CH-EAE is associated with increased lesion burden, myelin loss, axonal damage, and chemokine/cytokine expression when compared with RR-EAE. We further showed that inflammation and myelin loss continue to worsen in later stages of CH-EAE, whereas these features are largely resolved at the equivalent stage in RR-EAE. Additionally, axonal loss at these later stages is more severe in CH-EAE than in RR-EAE. We also demonstrated that CH-EAE is associated with a greater predominance of CD8(+) T cells in the CNS that exhibit MOG(35-55) antigen specificity. These studies therefore showed that, as early as the peak stage of disease, RR- and CH-EAE differ remarkably in their immune cell profile, chemokine/cytokine responses, and histopathological features. These data also indicated that this model of CH-EAE exhibits pathological features of a chronic-progressive disease profile and suggested that the sustained chronic phenotype is due to a combination of axonal loss, myelin loss, and continuing inflammation. 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19780195     DOI: 10.1002/glia.20935

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  50 in total

1.  Role of brain transmigrating neutrophils in depression-like behavior during systemic infection.

Authors:  A Aguilar-Valles; A Aguliar-Valles; J Kim; S Jung; B Woodside; G N Luheshi
Journal:  Mol Psychiatry       Date:  2013-10-15       Impact factor: 15.992

2.  Activating transcription factor 6α deficiency exacerbates oligodendrocyte death and myelin damage in immune-mediated demyelinating diseases.

Authors:  Sarrabeth Stone; Shuangchan Wu; Stephanie Jamison; Wilaiwan Durose; Jean Pierre Pallais; Wensheng Lin
Journal:  Glia       Date:  2018-02-13       Impact factor: 7.452

3.  Thalamus Degeneration and Inflammation in Two Distinct Multiple Sclerosis Animal Models.

Authors:  Nina Wagenknecht; Birte Becker; Miriam Scheld; Cordian Beyer; Tim Clarner; Tanja Hochstrasser; Markus Kipp
Journal:  J Mol Neurosci       Date:  2016-08-04       Impact factor: 3.444

4.  Low dose dextromethorphan attenuates moderate experimental autoimmune encephalomyelitis by inhibiting NOX2 and reducing peripheral immune cells infiltration in the spinal cord.

Authors:  Olga V Chechneva; Florian Mayrhofer; Daniel J Daugherty; David E Pleasure; Jau-Shyong Hong; Wenbin Deng
Journal:  Neurobiol Dis       Date:  2011-06-24       Impact factor: 5.996

5.  Monitoring diffuse injury during disease progression in experimental autoimmune encephalomyelitis with on resonance variable delay multiple pulse (onVDMP) CEST MRI.

Authors:  Aline M Thomas; Jiadi Xu; Peter A Calabresi; Peter C M van Zijl; Jeff W M Bulte
Journal:  Neuroimage       Date:  2019-10-09       Impact factor: 6.556

6.  Glatiramer acetate guards against rapid memory decline during relapsing-remitting experimental autoimmune encephalomyelitis.

Authors:  Patrizia LoPresti
Journal:  Neurochem Res       Date:  2014-12-07       Impact factor: 3.996

7.  An ανβ3 integrin-binding peptide ameliorates symptoms of chronic progressive experimental autoimmune encephalomyelitis by alleviating neuroinflammatory responses in mice.

Authors:  Fan Zhang; Jing Yang; Hong Jiang; Shu Han
Journal:  J Neuroimmune Pharmacol       Date:  2014-02-28       Impact factor: 4.147

Review 8.  Modeling the heterogeneity of multiple sclerosis in animals.

Authors:  Sarah B Simmons; Emily R Pierson; Sarah Y Lee; Joan M Goverman
Journal:  Trends Immunol       Date:  2013-05-21       Impact factor: 16.687

9.  Suppressor of Cytokine Signaling (SOCS)1 Regulates Interleukin-4 (IL-4)-activated Insulin Receptor Substrate (IRS)-2 Tyrosine Phosphorylation in Monocytes and Macrophages via the Proteasome.

Authors:  Sarah M McCormick; Nagaraj Gowda; Jessie X Fang; Nicola M Heller
Journal:  J Biol Chem       Date:  2016-08-09       Impact factor: 5.157

10.  Mechanisms and pharmacology of neuropathic pain in multiple sclerosis.

Authors:  T Iannitti; B J Kerr; B K Taylor
Journal:  Curr Top Behav Neurosci       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.